Board Member
Sarepta Therapeutics, Inc. (SRPT)Equibles does not estimate personal net worth.
Get an email with a short summary when Sarepta Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get SRPT alertsMichael Severino, M.D. is recorded as CEO and Board Member at Sarepta Therapeutics, Inc. (SRPT) since July 28, 2026. Sarepta Therapeutics, Inc. reported in an 8-K filed July 27, 2026 that Michael Severino, M.D. was appointed Class I director, effective July 28, 2026. Sarepta Therapeutics, Inc. reported in an 8-K filed July 27, 2026 that Michael Severino, M.D. was appointed Chief Executive Officer, effective July 28, 2026. Michael Severino, M.D. has spoken on 2 earnings calls and 2 other investor events across 1 company, most recently for Sarepta Therapeutics, Inc. on November 9, 2026. Sarepta Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Sarepta Therapeutics, Inc. includes Douglas Ingram (CEO and Board Member), M. Kathleen Behrens (Chairman), Ryan H. Wong (CFO) and 7 others.
“Also on July 23, 2026, the Board appointed Dr. Severino, effective as of the Effective Date, as a Class I director, to serve until the Company's 2028 annual meeting of stockholders.”
“On July 23, 2026, the Board of Directors (the "Board") of Sarepta Therapeutics, Inc. (the "Company") appointed Michael Severino, M.D. as Chief Executive Officer of the Company, effective July 28, 2026 (the "Effective Date").”
“Well, I see the setup of Sarepta as unique in a number of ways.”
“It has been a little over 90 days since I joined Sarepta, and I want to begin by sharing a few reflections from that time and how they are shaping my priorities for the company.”
“So near term, there are a number of important areas of focus. First of all, we want to continue to support and drive the business for our marketer products. As I mentioned, we have a cadre of marketed products, Elevitus, people obviously are very familiar with, and our PMO franchise, both very important to the company.”
“Good afternoon. and thank you for joining Sarepta Therapeutics' second quarter financial results conference call.”
2026-07-28–present
2026-07-28–present
Biotechnology · Healthcare
CEO, Board Member
2026-07-28–present
